本文關(guān)鍵詞： 姜黃素 固體脂質(zhì)納米粒 口服藥動(dòng)學(xué)　出處：《中國(guó)醫(yī)院藥學(xué)雜志》2015年04期 　論文類型：期刊論文

【摘要】：目的:研究姜黃素固體脂質(zhì)納米粒在SD大鼠體內(nèi)的口服藥動(dòng)學(xué)情況。方法:大鼠單劑量灌胃給予姜黃素固體脂質(zhì)納米粒和游離藥姜黃素,眼底靜脈叢取血,以醋酸乙酯處理血漿樣品,尼群地平為內(nèi)標(biāo),高效液相法(HPLC)測(cè)定血漿中姜黃素的含量,并用藥物與統(tǒng)計(jì)(Drug and Statistics,DAS)軟件分析處理藥動(dòng)學(xué)數(shù)據(jù)。結(jié)果:姜黃素固體脂質(zhì)納米粒和游離藥姜黃素在大鼠體內(nèi)的藥動(dòng)學(xué)行為均符合二室開(kāi)放模型,姜黃素固體脂質(zhì)納米粒和游離藥姜黃素的藥動(dòng)學(xué)參數(shù)分別如下:藥時(shí)曲線下面積(AUC0-t)為(798.00±64.44)μg·h·L-1和(108.78±14.22)μg·h·L-1,藥時(shí)曲線下總面積(AUC0-∞)為(939.49±114.18)μg·h·L-1和(126.99±28.14)μg·h·L-1,峰濃度(Cmax)為(93.84±5.66)μg·L-1和(72.46±2.66)μg·L-1,消除半衰期(t1/2)為(17.16±1.61)h和(4.71±1.18)h,姜黃素固體脂質(zhì)納米粒的AUC0-t、AUC0-∞、Cmax和t1/2分別提高了7.34,7.40,1.30和3.64倍。結(jié)論:姜黃素固體脂質(zhì)納米粒體內(nèi)消除慢,血藥濃度高,且明顯提高了姜黃素的口服生物利用度。
[Abstract]:Objective: to study the pharmacokinetics of curcumin solid lipid nanoparticles in SD rats. Methods: rats were given curcumin solid lipid nanoparticles and free curcumin respectively. The plasma samples were treated with ethyl acetate and nitrendipine was used as internal standard. The content of curcumin in plasma was determined by high performance liquid chromatography (HPLC). Drugs and statistics were used for drug and Statistics. Results: the pharmacokinetic behavior of curcumin solid lipid nanoparticles and free curcumin in rats was in accordance with the two-compartment open model. The pharmacokinetic parameters of curcumin solid lipid nanoparticles and curcumin were as follows: the area under the drug time curve (AUC0-t) was 798.00 鹵64.44 渭 g 路h 路L -1 and (. 108.78 鹵14.22 渭 g 路h 路L -1. The total area under the drug time curve was 939.49 鹵114.18 渭 g 路h 路L -1 and 126.99 鹵28.14 渭 g 路h 路L -1 respectively. The peak concentration of C _ (max) was 93.84 鹵5.66 渭 g 路L ~ (-1) and 72.46 鹵2.66 渭 g 路L ~ (-1). The elimination half-life was 17.16 鹵1.61h and 4.71 鹵1.18hrespectively, and the AUC0-tU AUC0- 鈭，

本文編號(hào)：1479457